14-67825518-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_001321817.2(RAD51B):c.-317C>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000107 in 1,613,712 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000072 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00011 ( 0 hom. )
Consequence
RAD51B
NM_001321817.2 5_prime_UTR_premature_start_codon_gain
NM_001321817.2 5_prime_UTR_premature_start_codon_gain
Scores
1
2
4
Clinical Significance
Conservation
PhyloP100: -0.907
Genes affected
RAD51B (HGNC:9822): (RAD51 paralog B) The protein encoded by this gene is a member of the RAD51 protein family. RAD51 family members are evolutionarily conserved proteins essential for DNA repair by homologous recombination. This protein has been shown to form a stable heterodimer with the family member RAD51C, which further interacts with the other family members, such as RAD51, XRCC2, and XRCC3. Overexpression of this gene was found to cause cell cycle G1 delay and cell apoptosis, which suggested a role of this protein in sensing DNA damage. Rearrangements between this locus and high mobility group AT-hook 2 (HMGA2, GeneID 8091) have been observed in uterine leiomyomata. [provided by RefSeq, Mar 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High AC in GnomAd4 at 11 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD51B | NM_133510.4 | c.139C>T | p.Arg47* | stop_gained | 3/11 | ENST00000471583.6 | NP_598194.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD51B | ENST00000471583.6 | c.139C>T | p.Arg47* | stop_gained | 3/11 | 1 | NM_133510.4 | ENSP00000418859.1 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152092Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
11
AN:
152092
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000147 AC: 37AN: 251286Hom.: 0 AF XY: 0.000177 AC XY: 24AN XY: 135802
GnomAD3 exomes
AF:
AC:
37
AN:
251286
Hom.:
AF XY:
AC XY:
24
AN XY:
135802
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000111 AC: 162AN: 1461502Hom.: 0 Cov.: 30 AF XY: 0.000114 AC XY: 83AN XY: 727056
GnomAD4 exome
AF:
AC:
162
AN:
1461502
Hom.:
Cov.:
30
AF XY:
AC XY:
83
AN XY:
727056
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152210Hom.: 0 Cov.: 32 AF XY: 0.0000940 AC XY: 7AN XY: 74438
GnomAD4 genome
AF:
AC:
11
AN:
152210
Hom.:
Cov.:
32
AF XY:
AC XY:
7
AN XY:
74438
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
21
Asia WGS
AF:
AC:
2
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 23, 2024 | The p.R47* variant (also known as c.139C>T), located in coding exon 2 of the RAD51B gene, results from a C to T substitution at nucleotide position 139. This changes the amino acid from an arginine to a stop codon within coding exon 2. This alteration is expected to result in protein truncation or nonsense-mediated mRNA decay. However, the evidence for this gene-disease relationship is limited; therefore, the clinical significance of this alteration is unclear. - |
Familial cancer of breast Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Biotechnology, Institute of Science, Nirma University | Apr 15, 2024 | The RAD51B a paralogue for RAD51, is found to play a role in breast and ovarian cancers. RAD51Bc.139C>T is a heterozygous dominant variant which has been classified as VUS. The variant has structural implication on the protein leading to its premature termination at Arg47. Further in-silico analysis indicates absence of interatction between RAD51B and RAD51C due to a loss of NTD region and Linker domain of the RAD51B. This disrupts the DNA damage repair further downstream. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | University of Washington Department of Laboratory Medicine, University of Washington | Nov 20, 2015 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at